Lexicon Pharmaceuticals CEO Michael Exton Buys $50K of Stock
Michael Exton, CEO, bought 30,064 shares of Lexicon Pharmaceuticals, Inc. at $1.66 a share, worth $50K in total on Nov 6, 2026. Shares held after the trade: 328,496 (+10.1%).
Lexicon Pharmaceuticals reported a net loss of $46.8 million for the nine months ended September 30, 2026, compared to $34.8 million in the prior year period. The company strengthened its balance sheet through common and preferred stock issuances, ending the period with $183.2 million in cash and short-term investments.
Lexicon Pharmaceuticals reported Q3 2026 financial results and provided clinical updates, including the completion of enrollment for its Phase 3 SONATA-HCM study. The company also confirmed it has achieved the safety data requirements for its ZYNQUISTA NDA resubmission in type 1 diabetes.
Term
3 months
“This quarter brought Lexicon into sharper focus as a cardiometabolic company and has positioned us to approach 2027 with strong momentum and multiple near-term potential catalysts and paths to value creation.”
Mike Exton, Ph.D., Lexicon’s chief executive officer and director
“As we prepare for several important milestones across our portfolio, we remain focused on investing prudently to support execution and position the Company for long-term success.”